No Data
No Data
CRISPR Therapeutics COO to Step Down
Crispr Therapeutics : Oper Chief Julianne Bruno Stepping Down to Pursue External Opportunities, Effective April 11 >CRSP
Press Release: CRISPR Therapeutics Announces Transition of Chief Operating Officer
This CRISPR Therapeutics Insider Increased Their Holding In The Last Year
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $97
Is CRISPR Therapeutics AG (CRSP) a Promising Biotech Stock According to Wall Street Analysts
Unlock the Full List
sooogod : nbis.
GOGOY : Tem will be the next